BURZYNSKI RESEARCH INSTITUTE INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BURZYNSKI RESEARCH INSTITUTE INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $0 | May 20, 2025 |
| FY2025 | Feb 29, 2024 | $0 | May 20, 2025 |
| FY2024 | Feb 28, 2023 | $0 | May 29, 2024 |
| FY2023 | Feb 28, 2022 | $0 | May 25, 2023 |
| FY2022 | Feb 28, 2021 | $0 | May 26, 2022 |
| FY2021 | Feb 29, 2020 | $0 | May 24, 2021 |
| FY2020 | Feb 28, 2019 | $0 | May 28, 2020 |
| FY2019 | Feb 28, 2018 | $0 | May 29, 2019 |
| FY2018 | Feb 28, 2017 | $0 | May 22, 2018 |
| FY2017 | Feb 29, 2016 | $0 | May 11, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($1.39M) | May 20, 2025 |
| FY2025 | Feb 29, 2024 | ($1.34M) | May 20, 2025 |
| FY2024 | Feb 28, 2023 | ($916.3K) | May 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($1.39M) | May 20, 2025 |
| FY2025 | Feb 29, 2024 | ($1.34M) | May 20, 2025 |
| FY2024 | Feb 28, 2023 | ($916.3K) | May 29, 2024 |
| FY2023 | Feb 28, 2022 | ($976.7K) | May 25, 2023 |
| FY2022 | Feb 28, 2021 | ($1.30M) | May 26, 2022 |
| FY2021 | Feb 29, 2020 | ($1.63M) | May 24, 2021 |
| FY2020 | Feb 28, 2019 | ($1.64M) | May 28, 2020 |
| FY2019 | Feb 28, 2018 | ($1.61M) | May 29, 2019 |
| FY2018 | Feb 28, 2017 | ($1.50M) | May 22, 2018 |
| FY2017 | Feb 29, 2016 | ($2.01M) | May 11, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $1.05M | May 20, 2025 |
| FY2025 | Feb 29, 2024 | $865.0K | May 20, 2025 |
| FY2024 | Feb 28, 2023 | $718.5K | May 29, 2024 |
| FY2023 | Feb 28, 2022 | $759.5K | May 25, 2023 |
| FY2022 | Feb 28, 2021 | $1.02M | May 26, 2022 |
| FY2021 | Feb 29, 2020 | $1.20M | May 24, 2021 |
| FY2020 | Feb 28, 2019 | $1.15M | May 28, 2020 |
| FY2019 | Feb 28, 2018 | $1.28M | May 29, 2019 |
| FY2018 | Feb 28, 2017 | $1.32M | May 22, 2018 |
| FY2017 | Feb 29, 2016 | $1.85M | May 11, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($388.5K) | May 20, 2025 |
| FY2025 | Feb 29, 2024 | ($523.8K) | May 20, 2025 |
| FY2024 | Feb 28, 2023 | ($249.5K) | May 29, 2024 |
| FY2023 | Feb 28, 2022 | ($325.1K) | May 25, 2023 |
| FY2022 | Feb 28, 2021 | ($394.4K) | May 26, 2022 |
| FY2021 | Feb 29, 2020 | ($530.1K) | May 24, 2021 |
| FY2020 | Feb 28, 2019 | ($477.5K) | May 28, 2020 |
| FY2019 | Feb 28, 2018 | ($319.5K) | May 29, 2019 |
| FY2018 | Feb 28, 2017 | ($314.5K) | May 22, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $847 | May 20, 2025 |
| FY2025 | Feb 29, 2024 | $2.3K | May 20, 2025 |
| FY2024 | Feb 28, 2023 | $1.9K | May 29, 2024 |
| FY2023 | Feb 28, 2022 | $4.7K | May 25, 2023 |
| FY2022 | Feb 28, 2021 | $956 | May 26, 2022 |
| FY2021 | Feb 29, 2020 | $19.9K | May 24, 2021 |
| FY2020 | Feb 28, 2019 | $22.2K | May 28, 2020 |
| FY2019 | Feb 28, 2018 | $28.9K | May 29, 2019 |
| FY2018 | Feb 28, 2017 | $10.7K | May 22, 2018 |
| FY2017 | Feb 29, 2016 | $4.0K | May 11, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $42.5K | May 20, 2025 |
| FY2025 | Feb 29, 2024 | $27.4K | May 20, 2025 |
| FY2024 | Feb 28, 2023 | $15.7K | May 29, 2024 |
| FY2023 | Feb 28, 2022 | $3.5K | May 25, 2023 |
| FY2022 | Feb 28, 2021 | $46.8K | May 26, 2022 |
| FY2021 | Feb 29, 2020 | $172.4K | May 24, 2021 |
| FY2020 | Feb 28, 2019 | $208.8K | May 28, 2020 |
| FY2019 | Feb 28, 2018 | $136.6K | May 29, 2019 |
| FY2018 | Feb 28, 2017 | $43.7K | May 22, 2018 |
| FY2017 | Feb 29, 2016 | $105.0K | May 11, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($41.6K) | May 20, 2025 |
| FY2025 | Feb 29, 2024 | ($25.1K) | May 20, 2025 |
| FY2025 | Feb 28, 2023 | ($13.7K) | May 20, 2025 |
| FY2024 | Feb 28, 2022 | $1.2K | May 29, 2024 |
| FY2023 | Feb 28, 2021 | ($45.8K) | May 25, 2023 |
| FY2022 | Feb 29, 2020 | ($152.6K) | May 26, 2022 |
| FY2021 | Feb 28, 2019 | ($186.6K) | May 24, 2021 |
| FY2020 | Feb 28, 2018 | ($107.7K) | May 28, 2020 |
| FY2019 | Feb 28, 2017 | ($33.0K) | May 29, 2019 |
| FY2018 | Feb 29, 2016 | ($101.0K) | May 22, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($129.48M) | May 20, 2025 |
| FY2025 | Feb 29, 2024 | ($128.09M) | May 20, 2025 |
| FY2024 | Feb 28, 2023 | ($126.75M) | May 29, 2024 |
| FY2023 | Feb 28, 2022 | ($125.84M) | May 25, 2023 |
| FY2022 | Feb 28, 2021 | ($124.86M) | May 26, 2022 |
| FY2021 | Feb 29, 2020 | ($123.66M) | May 24, 2021 |
| FY2020 | Feb 28, 2019 | ($122.02M) | May 28, 2020 |
| FY2019 | Feb 28, 2018 | ($120.39M) | May 29, 2019 |
| FY2018 | Feb 28, 2017 | ($118.77M) | May 22, 2018 |
| FY2017 | Feb 29, 2016 | ($117.27M) | May 11, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $847 | May 20, 2025 |
| FY2025 | Feb 29, 2024 | $1.3K | May 20, 2025 |
| FY2024 | Feb 28, 2023 | $934 | May 29, 2024 |
| FY2023 | Feb 28, 2022 | $3.4K | May 25, 2023 |
| FY2022 | Feb 28, 2021 | $62 | May 26, 2022 |
| FY2021 | Feb 29, 2020 | $163 | May 24, 2021 |
| FY2020 | Feb 28, 2019 | $708 | May 28, 2020 |
| FY2019 | Feb 28, 2018 | $506 | May 29, 2019 |
| FY2018 | Feb 28, 2017 | $731 | May 22, 2018 |
| FY2018 | Feb 29, 2016 | $3.3K | May 22, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 0 | May 20, 2025 |
| FY2025 | Feb 29, 2024 | 0 | May 20, 2025 |
| FY2024 | Feb 28, 2023 | 0 | May 29, 2024 |
| FY2023 | Feb 28, 2022 | 0 | May 25, 2023 |
| FY2022 | Feb 28, 2021 | 0 | May 26, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 0 | May 20, 2025 |
| FY2025 | Feb 29, 2024 | 0 | May 20, 2025 |
| FY2024 | Feb 28, 2023 | 0 | May 29, 2024 |
| FY2023 | Feb 28, 2022 | 0 | May 25, 2023 |
| FY2022 | Feb 28, 2021 | 0 | May 26, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 131.45M | May 20, 2025 |
| FY2025 | Feb 29, 2024 | 131.45M | May 20, 2025 |
| FY2024 | Feb 28, 2023 | 131.45M | May 29, 2024 |
| FY2023 | Feb 28, 2022 | 131.45M | May 25, 2023 |
| FY2022 | Feb 28, 2021 | 131.45M | May 26, 2022 |
| FY2021 | Feb 29, 2020 | 131.45M | May 24, 2021 |
| FY2020 | Feb 28, 2019 | 131.45M | May 28, 2020 |
| FY2019 | Feb 28, 2018 | 131.45M | May 29, 2019 |
| FY2018 | Feb 28, 2017 | 131.45M | May 22, 2018 |
| FY2017 | Feb 29, 2016 | 131.45M | May 11, 2017 |